Because SHIP2 plays a central role in the Aβ-induced abnormality of both neuronal actin and microtubule, it can be considered as a powerful therapeutic target for Alzheimer’s disease. The gene discussed is INPPL1; the disease is early-onset autosomal dominant Alzheimer disease.